What StimLabs’ DermaForm approval reveals about the future of regenerative wound care
StimLabs has secured FDA clearance for DermaForm, expanding its wound care portfolio. Find out what this changes for clinicians and the market.
Medical Devices & Diagnostics
Medical Devices & Diagnostics
Can targeting neuropathy reverse tissue death? What the Rapid Nexus study means for chronic wound care
New study shows neuropathy reversal can restore healing in tissue facing amputation. Find out how Rapid Nexus could reshape wound care.
Pharma & Biotech
Is Zegen-15 the breakthrough diabetic foot ulcer therapy insurers will finally cover?
Zegenex, a Pittsburgh-based biotechnology company focused on regenerative wound care, has secured a $215,000 social-impact investment from the Richard King Mellon Foundation to accelerate formulation and preclinical development of Zegen-15, a first-in-class small-molecule cream targeting chronic wounds, including diabetic foot ulcers. The funding positions Zegenex to begin clinical trials by the end of 2026 and